← Back to Search

Immunoglobulin

C-IVIG for Coronavirus

Phase 2 & 3
Waitlist Available
Led By Shaukat Ali, PhD
Research Sponsored by Dow University of Health Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group

Summary

Severe ill Patients will be enrolled in the study (n=310) after duly filled consent forms. Recipients will be divided into 2 group, each group contain 155 patients to compare Safety and efficacy of patients in Clinical Trial phase II/III. One Group will receive 0.15g/kg single dose of anti COVID 19 intravenously immunoglobulin (C-IVIG) develop from convalescent plasma of recovered patients from COVID 19, along with Standard of care. The Comparator group will only receive standard of Care

Eligible Conditions
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
28 day Mortality
Secondary study objectives
Clinical Status of follow-up days according to 7-Catergory Ordinal Scale
Immediate and serious adverse event during hospital Stay
change in C-Reactive Protein (CRP) levels
+4 more

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: C-IVIGExperimental Treatment1 Intervention
The intervention group will receive the single dose of C-IVIG (0.15g/kg) with Standard of Care
Group II: ControlActive Control1 Intervention
The Control group will be receive Standard of care only

Find a Location

Who is running the clinical trial?

Dow University of Health SciencesLead Sponsor
153 Previous Clinical Trials
46,050 Total Patients Enrolled
Higher Education Commission (Pakistan)OTHER
7 Previous Clinical Trials
631 Total Patients Enrolled
Shaukat Ali, PhDPrincipal InvestigatorDow University of Health Sciences, Principal Dow College of Biotechnology
~74 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top